Increased CD4 + and CD8 + VISTA expression has been reported after ipilimumab therapy in patients with prostate cancer, with increased PD-L1 and VISTA inhibitory molecules on independent subsets of macrophages [16]. The gene discussed is VSIR; the disease is prostate carcinoma.